A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)

Daniel Heudobler, Christian Schulz, Jürgen R. Fischer, Peter Staib, Thomas Wehler, Thomas Südhoff, Thomas Schichtl, Jochen Wilke, Joachim Hahn, Florian Lüke, Martin Vogelhuber, Sebastian Klobuch, Tobias Pukrop, Wolfgang Herr, Swantje Held, Kristine Beckers, Gauthier Bouche, Albrecht Reichle

Open source

DOI: 10.3389/fphar.2021.599598
Published: 2021-03-16
Container: Frontiers in Pharmacology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2021.599598,
  title = {A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)},
  author = {Daniel Heudobler and Christian Schulz and Jürgen R. Fischer and Peter Staib and Thomas Wehler and Thomas Südhoff and Thomas Schichtl and Jochen Wilke and Joachim Hahn and Florian Lüke and Martin Vogelhuber and Sebastian Klobuch and Tobias Pukrop and Wolfgang Herr and Swantje Held and Kristine Beckers and Gauthier Bouche and Albrecht Reichle},
  year = {2021},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2021.599598},
  url = {https://doi.org/10.3389/fphar.2021.599598}
}

RIS

TY  - JOUR
TI  - A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)
AU  - Daniel Heudobler
AU  - Christian Schulz
AU  - Jürgen R. Fischer
AU  - Peter Staib
AU  - Thomas Wehler
AU  - Thomas Südhoff
AU  - Thomas Schichtl
AU  - Jochen Wilke
AU  - Joachim Hahn
AU  - Florian Lüke
AU  - Martin Vogelhuber
AU  - Sebastian Klobuch
AU  - Tobias Pukrop
AU  - Wolfgang Herr
AU  - Swantje Held
AU  - Kristine Beckers
AU  - Gauthier Bouche
AU  - Albrecht Reichle
PY  - 2021
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2021.599598
UR  - https://doi.org/10.3389/fphar.2021.599598
ER  -

APA

Heudobler, D., Schulz, C., Fischer, J. R., Staib, P., Wehler, T., Südhoff, T., Schichtl, T., Wilke, J., Hahn, J., Lüke, F., Vogelhuber, M., Klobuch, S., Pukrop, T., Herr, W., Held, S., Beckers, K., Bouche, G., & Reichle, A. (2021). A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.599598

Source records

crossref · retrieved 2026-09-26T17:53:50.150Z